Life Sciences

Holliston-based Harvard Bioscience has spun off part of its business, which makes regenerative medical devices, the company announced.

Biotech giant Genzyme will expand its Framingham campus with an $80-million processing facility that it says will “significantly” expand its purification capacity to support growth over the next few years, the Cambridge-based company announced today.

Medical device manufacturer Grove Instruments Inc. of Worcester has closed a $3.3 million offering of preferred stock that it says will help fund clinical testing of a new device.

Waters Corp. unveiled a device that week that the Milford-based company said would remove barriers to accessing molecular chemical data.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company that's developing cancer-killing drugs, announced it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.

Verax Biomedical announced the completion of a $12 million round of financing to support the ongoing commercialization of its product, the Platelet PGD Test.

Work is nearly complete on a 60,000-square-foot, three-story addition to PerkinElmer's Hopkinton campus, the company said.

Boston Biomedical Associates (BBA) will be moving its 52 workers to a 17,000-square-foot space in Marlborough, the company announced Thursday.

Precision Optics of Gardner increased fourth-quarter revenue 4 percent and finished its fiscal year in June with a 17-percent jump in revenue, while cutting its quarterly loss, the maker of optical systems announced this week.

A federal appellate court ruled last week that a planned generic sleep aid would infringe on Sunovion Pharmaceuticals Inc. patent for its Lunesta drug, rerversing a lower-court ruling against the Marlborough firm.